ifosfamide has been researched along with Central Nervous System Diseases in 15 studies
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count." | 9.07 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. ( Craft, AW; Lowis, SP; Pearson, AD; Reid, MM, 1993) |
| "Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count." | 5.07 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. ( Craft, AW; Lowis, SP; Pearson, AD; Reid, MM, 1993) |
| "In a phase II trial of ifosfamide 2 g/m2 days 1 to 4 with mesna uroprotection in 124 patients who had previously failed treatment for sarcomas, 3% achieved a complete response (CR), and 18% had a CR or partial response (PR)." | 5.06 | Dana-Farber Cancer Institute studies in advanced sarcoma. ( Antman, KH; Elias, A, 1990) |
| " The predictive capability of a published nomogram is restricted by differences in dosage regimens and encephalopathic classifications." | 2.38 | Ifosfamide-induced neurotoxicity: a case report and review of the literature. ( Eaton, VE; Miller, LJ, 1992) |
| "Ifosfamide/mesna treatment of 50 patients with pediatric malignant solid tumors was associated with the development of neurotoxic signs and symptoms in 11 of these individuals who received 29 courses of treatment." | 1.27 | Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. ( Douglass, E; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Igarashi, M; Meyer, WH; Pratt, CB; Thompson, E; Wilimas, J, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (46.67) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peddi, PF | 1 |
| Peddi, S | 1 |
| Santos, ES | 1 |
| Morgensztern, D | 1 |
| Heim, ME | 1 |
| Fiene, R | 1 |
| Schick, E | 1 |
| Wolpert, E | 1 |
| Queisser, W | 1 |
| Lowis, SP | 1 |
| Pearson, AD | 1 |
| Reid, MM | 1 |
| Craft, AW | 1 |
| Geissler, RG | 1 |
| Bergmann, L | 1 |
| Hacker, H | 1 |
| Knupp, B | 1 |
| Walker, B | 1 |
| Hoelzer, D | 1 |
| González-Martín, A | 1 |
| Crespo, C | 1 |
| García-López, JL | 1 |
| Pedraza, M | 1 |
| Garrido, P | 1 |
| Lastra, E | 1 |
| Moyano, A | 1 |
| Miller, LJ | 1 |
| Eaton, VE | 1 |
| Lotz, JP | 1 |
| Machover, D | 1 |
| Malassagne, B | 1 |
| Hingh, B | 1 |
| Donsimoni, R | 1 |
| Gumus, Y | 1 |
| Gerota, J | 1 |
| Lam, Y | 1 |
| Tulliez, M | 1 |
| Marsiglia, H | 1 |
| Lewis, LD | 1 |
| Meanwell, CA | 2 |
| Antman, KH | 1 |
| Elias, A | 1 |
| Atherton, P | 1 |
| Buxton, J | 1 |
| Honigsberger, L | 1 |
| Mould, J | 1 |
| Mould, JJ | 1 |
| Blackledge, G | 1 |
| Lawton, FG | 1 |
| Stuart, NS | 1 |
| Kavanagh, J | 1 |
| Latief, TN | 1 |
| Spooner, D | 1 |
| Chetiyawardana, AD | 1 |
| Pratt, CB | 1 |
| Green, AA | 1 |
| Horowitz, ME | 1 |
| Meyer, WH | 1 |
| Etcubanas, E | 1 |
| Douglass, E | 1 |
| Hayes, FA | 1 |
| Thompson, E | 1 |
| Wilimas, J | 1 |
| Igarashi, M | 1 |
| Delépine, N | 1 |
| Taillard, F | 1 |
| Desbois, JG | 1 |
| Cornille, H | 1 |
| Delépine, G | 1 |
| Jasmin, C | 1 |
| Mehta, AC | 1 |
| Calvert, RT | 1 |
| Kellie, SJ | 1 |
| Pritchard, J | 1 |
| Bowman, A | 1 |
| de Kraker, J | 1 |
| Lilleyman, JS | 1 |
2 reviews available for ifosfamide and Central Nervous System Diseases
| Article | Year |
|---|---|
Central nervous system toxicities of chemotherapeutic agents.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Cisplatin; Cytarabine; Fluorouracil; Humans; | 2014 |
Ifosfamide-induced neurotoxicity: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Humans; Ifos | 1992 |
4 trials available for ifosfamide and Central Nervous System Diseases
| Article | Year |
|---|---|
Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Child, Preschool; C | 1993 |
Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Drug A | 2002 |
Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati | 1991 |
Dana-Farber Cancer Institute studies in advanced sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1990 |
9 other studies available for ifosfamide and Central Nervous System Diseases
| Article | Year |
|---|---|
Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.
Topics: Adult; Aged; Central Nervous System Diseases; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney N | 1981 |
Severe central nervous adverse effect of intrathecal chemotherapy in a 16-yr-old patient with Burkitt's type lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain; Burkitt Lymphoma; Central Nervous | 1997 |
Ifosfamide pharmacokinetics and neurotoxicity.
Topics: Adult; Central Nervous System Diseases; Drug Administration Schedule; Drug Therapy, Combination; Hum | 1990 |
Drug-induced encephalopathy after previous ifosfamide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Diseases; Female; | 1988 |
Phase II study of ifosfamide in cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Central Nervo | 1986 |
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; | 1986 |
CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Central Nervous System D | 1986 |
Determination of ifosfamide in plasma by gas chromatography with nitrogen detector.
Topics: Central Nervous System Diseases; Chromatography, Gas; Humans; Ifosfamide; Indicators and Reagents; N | 1987 |
Ifosfamide neurotoxicity in children.
Topics: Adolescent; Adult; Central Nervous System Diseases; Child; Drug Evaluation; Female; Humans; Ifosfami | 1987 |